Description
Bacteriostatic water (bac water) is sold separately.
CJC-1295 and ipamorelin are studied for complementary effects on growth-hormone signalling through GHRH and ghrelin-receptor pathways.
Potential Benefits — Research Is Ongoing
These are mechanistic possibilities from growth-hormone-releasing peptide research, not established human benefits of the CJC no-DAC/ipamorelin blend. Long-acting CJC-1295 DAC trial results do not validate the no-DAC form.
- Natural growth-hormone release: May stimulate the body’s own growth-hormone secretion.
- Growth-related tissue signalling: May influence downstream signals involved in tissue maintenance.
- Body-composition pathways: May influence growth-hormone-related fat and protein metabolism.
Research sources: Ipamorelin secretagogue study.
Research Overview
CJC-related GHRH analogues and ipamorelin are studied as growth-hormone secretagogues: compounds that stimulate hormone release rather than supply growth hormone directly. Published human experiments have measured hormone responses and pharmacokinetics of the individual compounds. They do not establish the benefits of this combined research presentation.
Mechanism / Pathway
GHRH analogues act through the growth-hormone-releasing hormone receptor, while ipamorelin acts through the ghrelin receptor pathway. These pathways influence pituitary GH secretion and downstream IGF-1 signalling. Changes in hormone levels are not themselves a measure of improved health or performance.
Important Research Information
The cited CJC-1295 trial studied a long-acting formulation. Its prolonged effects must not be attributed to no-DAC material or another analogue; exact chemical identity and formulation must be confirmed separately. The combination has not been validated by the cited trials for bodybuilding, sleep improvement or anti-ageing, and these studies do not establish human-use safety for this vial.
Published Research
- [1] Teichman et al. (2006): Long-acting CJC-1295 and GH/IGF-1 in healthy adults.
- [2] Gobburu et al. (1999): Ipamorelin pharmacokinetic/pharmacodynamic modelling in volunteers.
Scientific Profile
- Components: CJC-1295 5 mg + Ipamorelin 5 mg; 10 mg total
- Compound classes: GHRH-related analogue plus ghrelin-receptor agonist
- Identity limitation: Confirm the exact CJC variant from batch documentation; long-acting CJC-1295 findings cannot be assigned to no-DAC material
- Mixture identity: A blend has no single molecular formula or molecular weight
Research Areas
- GHRH and ghrelin-receptor signalling
- GH and downstream IGF-1 biomarker responses
- Variant-specific pharmacokinetics and limitations of combination research
CJC-1295 5 mg + Ipamorelin 5 mg Vial
CJC-1295 + Ipamorelin, supplied as lyophilised powder in a B&A Premium vial with a holographic product label.
About this vial presentation
CJC-1295 5 mg + Ipamorelin 5 mg Vial is supplied as one vial in the B&A Premium range. The labelled amount of 5 mg + 5 mg refers to the total contents of the vial, rather than a dose or liquid volume. Use the actual batch label to confirm identity, total dry content, storage and expiry information. This vial is supplied as lyophilised powder, not as a liquid or ready-made solution.
Browse the vial collection to compare product names, quantities and formats. Bacteriostatic water is sold separately; this does not establish that it is compatible with this formulation. For documentation relating to CJC-1295 5 mg + Ipamorelin 5 mg Vial, contact B&A Premium with the batch reference.
Product details
- Contents: CJC-1295 + Ipamorelin
- Labelled amount per vial: 5 mg + 5 mg
- Presentation: lyophilised powder in a vial
- Pack: 1 vial
Storage
Keep refrigerated at 2–8°C and protected from light. Follow the batch label for expiry and handling instructions.
Important research information
For research use only. The labelled amount is the total content per vial, not a dose. Product artwork is illustrative; consult the supplied label for batch-specific details.
Looking for another presentation? View the CJC-1295 5 mg + Ipamorelin 5 mg prefilled pen. Compare each listing’s format and labelled contents; vial powder and prefilled pens are separate presentations.
Warnings, Contraindications & Safety Information
Research use only. This is an evidence-limited safety summary, not a package insert, complete prescribing information or permission for self-administration. References to licensed medicines describe those specific products; they do not establish B&A product approval, equivalence or safety.
Contraindications & Who Should Avoid Exposure
A clinically validated contraindication list for this exact research presentation has not been established. That absence is not evidence of safety. Do not expose a person with a known allergy to a labelled ingredient or excipient.
Warnings & Precautions
This research presentation has not been established as safe for human administration. Do not use during pregnancy or breastfeeding, or in children. A serious medical condition, including cancer or significant liver or kidney disease, requires professional assessment; this page cannot establish suitability. CJC-1295 research documents GH/IGF-1 elevation. Clinical monitoring requirements and safety cannot be transferred between CJC variants or assumed for a CJC/ipamorelin blend.
Possible Adverse Reactions
Reliable frequencies and a complete human adverse-reaction profile for this exact product are unavailable. Allergy, local irritation and contamination-related harm remain possible; absence of reports does not establish absence of risk.
Drug & Supplement Interactions
Drug and supplement interactions have not been adequately characterised for this presentation. Do not assume that combining it with prescription medicines, hormones or other research compounds is safe. Give a clinician the full ingredient list if exposure has occurred.
When to Seek Urgent Help
Seek emergency care for difficulty breathing, swelling of the face or throat, collapse, severe persistent abdominal pain, or repeated vomiting with inability to keep fluids down. Stop further exposure and show the clinician the product label and ingredient list.
Handling & Storage Cautions
Follow the actual product label and batch-specific expiry information. Do not use damaged, contaminated or unexpectedly changed material. Powder appearance, refrigeration or addition of bacteriostatic water does not prove sterility, compatibility or a safe shelf life. Do not share needles, pens or opened material between people.
Safety references: Variant-specific CJC-1295 trial. Information reviewed 20 October 2026.
Reviews
There are no reviews yet.